Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study
Authors' conclusion
CZP showed a longer retention rate than mAB and ETA in patients with very high RF levels (≥200 IU/mL), while these differences were absent in patients with <200 IU/mL levels.
Study context
- Population
- Patients with RA treated with any tumour necrosis factor inhibitors (TNFi), stratified by baseline rheumatoid factor (RF) (cut-off third quartile: <200 and ≥200 IU/mL)752 treatments in 638 individuals
- Participants
- 752 patients
- Exposure
- Certolizumab pegol (CZP) vs monoclonal antibodies (mAB) vs etanercept (ETA), by baseline RF level
- CZPn = 132
- mABn = 439reference
- ETAn = 181reference
- Outcome
- TNFi retention rate according to baseline RF level
Methodological detailslongitudinal, multicentre, propensity-score matched sensitivity analysis
- Longitudinal
- Multicentre
- Propensity-score matched sensitivity analysis
Main finding
As reported in the abstract
Retention rate, RF ≥200 IU/mL (propensity-score matched)
Hazard ratio (95% CI)
CZPvs mAB
2.3(1.2–4.3)
CZPvs ETA
2.8(1.5–5.2)
Observational data: associations, not effects.
Original publication
Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study. RMD Open. Published 23 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →